Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Research & Development: 2015-2024

Historic Research & Development for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $64.6 million.

  • Seres Therapeutics' Research & Development fell 23.35% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 32.87%. This contributed to the annual value of $64.6 million for FY2024, which is 45.07% down from last year.
  • Latest data reveals that Seres Therapeutics reported Research & Development of $64.6 million as of FY2024, which was down 45.07% from $117.6 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Research & Development peaked at $141.9 million during FY2021, and registered a low of $64.6 million during FY2024.
  • Moreover, its 3-year median value for Research & Development was $109.7 million (2022), whereas its average is $97.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 56.66% in 2021, then slumped by 45.07% in 2024.
  • Over the past 5 years, Seres Therapeutics' Research & Development (Yearly) stood at $90.6 million in 2020, then spiked by 56.66% to $141.9 million in 2021, then fell by 22.72% to $109.7 million in 2022, then climbed by 7.25% to $117.6 million in 2023, then tumbled by 45.07% to $64.6 million in 2024.